US2505634A - 4-pyridone-nu-carboxylic acids - Google Patents
4-pyridone-nu-carboxylic acids Download PDFInfo
- Publication number
- US2505634A US2505634A US777864A US77786447A US2505634A US 2505634 A US2505634 A US 2505634A US 777864 A US777864 A US 777864A US 77786447 A US77786447 A US 77786447A US 2505634 A US2505634 A US 2505634A
- Authority
- US
- United States
- Prior art keywords
- pyridone
- diiodo
- acid
- alpha
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
Definitions
- This invention relates to halogenatedpyridone derivatives of carboxylicacids capable of forming water soluble salts with inorganic and organic bases.
- My new compounds havethe formula 'L-COOH where Y is a divalent hydrocarbonradical of from to 9 carbon atoms. They are generally used in the form of a Water soluble salt derived from an inorganic or organic base.
- These compounds may be prepared by the reaction of 3,5-diiodo-4-pyridone and a halo-carboxylic acid containing from 6 to carbon atoms in alkaline solution.
- a halo-carboxylic acid containing from 6 to carbon atoms in alkaline solution.
- R is an alkyl group offrom 4* to 8 carbon atoms.
- the diethanolamine salts of my new compounds have been found to give very good radiograms of the gall bladder at relatively low dosage levels upon intravenous administration, and to be relatively free from physiological side effects. They form colorless solutions in contrast to the sodium salt of tetraiodophenolphthalein which forms a dark blue solution, rendering it difficult to determine whether all of the substance is in solution.
- Thetoxicities of the compounds are unusually low for this type of molecule and so offer promise as intravenous cholecystographic agents, an application hitherto limited to the unsatisfactory tetraiodophenolphthalein.
- Intravenous. administration has certain advantages over oral use; smaller quantities of radiopaque are necessary with a greater degree of certainty of concentration in theucirculatory system and subsequently the gall bladder, and the. administration and radiographlc procedure is. completed in a much. shorter, time.
- Heating with stirring is continued for one and one-quarter hours longer, after which the mixture is cooled and carbon dioxide passed in until the solution is acid to phenylphthalein and all of the unreacted 3,5-diiodo-4- pyridone has been precipitated.
- the solid about 20 g., is filtered, and the filtrate is cooled in ice and acidified with hydrochloric acid.
- a gum precipitates which is filtered and dissolved in alco- 1101.
- the alcohol solution is decolorized with activated charcoal, filtered, and diluted with an equal volume of water. Upon cooling and standing, the product crystallizes and is filtered, dissolved in ether, dried over anhydrous sodium sulfate, and again decolorized.
- EXAMPLE 5 Alpha-n-octyZ-3,5-diiodo-4-py'rid0ne-N-acetic acid 3,5-diiodo-4-pyridone (35 g.) and 25.1 g. of 2- bromodecanoic acid are caused to react in the same manner as the components in Example 1.
- the acids prepared in the above examples, and others within the scope of the invention can be dissolved in an aqueous solution of an equivalent amount of a suitable inorganic or organic base.
- suitable bases are those which are innocuous and otherwise therapeutically acceptable to the organism; for example, sodium hydroxide, diethylamine and diethanolamine.
- Alpha isoamyl 3,5 diioclo 4 pyridone- N-acetic acid having the formula onaonornonl-oruo OOH and salts thereof.
- Alpha-amyl-3,5-diiodo-4-pyridone-N-acetic acid having the formula I CHaCHaCHiCH:CHa-CHG O OH and salts thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
Description
Patented Apr. 25, 1950 I-PYBIDONE-N-CARBOXY-IJIG ACIDS Sydney Archer, Albany, N. Yaassignor to, Sterling Drug Inc., Wilmington, Del.,,a. corporation of.
Delaware No Drawing. Applicationxflctolierrt; 19147, SeriaLNo. 777,864
9 Claimsa This invention relates to halogenatedpyridone derivatives of carboxylicacids capable of forming water soluble salts with inorganic and organic bases.
My new compounds havethe formula 'L-COOH where Y is a divalent hydrocarbonradical of from to 9 carbon atoms. They are generally used in the form of a Water soluble salt derived from an inorganic or organic base.
These compounds may be prepared by the reaction of 3,5-diiodo-4-pyridone and a halo-carboxylic acid containing from 6 to carbon atoms in alkaline solution. However, in'view of the distinctly greater availability of the alpha-halo-ca-rboxylic acids as compared with the beta, gamma, etc., derivatives, I prefer to prepare'anduse compounds of the formula where R is an alkyl group offrom 4* to 8 carbon atoms.
The lower homologues of my new compounds are already known. Thus 3,5-diiodo-4-pyridone- N-acetic acid and its salts, in particular the diethanolamine salt have been described in Reitmann, U. S. Patent 1,993,039, and Reitmann and Hecht, U. S. Patent 2,064,944, and these compounds have proved of considerable value; as X-ray contrast media; These substances are used in intravenous urography and excretion and retrograde pyelography.
It might be assumed from the action of these lower homologues that my new compounds would also be urographic agents. However, it has been found they concentrate in the bile rather than pass through the urinary tract, so that they are cholecystographic rather than urographic agents. It would appearthat when Y in the above-fore mula contains less than. about doarbon atoms.
the moleculelacksthe characteristics necessary for concentrationinthe gallbladder.
The. contrast media which. have been used up to. the presenttime for oral cholecystography are not entirely satisfactory. Tetraiodophenolphthalein frequently causes violent physiological reactions. 2 -(4,-hydroXy.- 3.,5 diiodophenyl) quinoline-scarboxylic acid ismuch too toxic. 2- (4-hydroxy-3,5 diiodophenyl) alpha-phenylpropionic acid is better than the others, but cocasionally produces pain. on urination, interferes with the rate of emptying of the gall bladder following'a fatty'meal, causes a burning sensation in the throat, or produces nausea, vomiting and diarrhea. This substance. is, moreover, too toxic to be used for intravenous cholecystography, and tetraiodophenolphthalein, although used for this purpose, .has:a toxicity level which is dangerously high intaddition to other drawbacks.
The diethanolamine salts of my new compounds have been found to give very good radiograms of the gall bladder at relatively low dosage levels upon intravenous administration, and to be relatively free from physiological side effects. They form colorless solutions in contrast to the sodium salt of tetraiodophenolphthalein which forms a dark blue solution, rendering it difficult to determine whether all of the substance is in solution. Thetoxicities of the compoundsare unusually low for this type of molecule and so offer promise as intravenous cholecystographic agents, an application hitherto limited to the unsatisfactory tetraiodophenolphthalein. Intravenous. administration has certain advantages over oral use; smaller quantities of radiopaque are necessary with a greater degree of certainty of concentration in theucirculatory system and subsequently the gall bladder, and the. administration and radiographlc procedure is. completed in a much. shorter, time.
These new compounds can be prepared by treatment .of an aqueous solution of. 3,5-diioclo-4-pyri done-(Dohrn;and Diedric-h, Ann, 494, 292 (1932),, and. German Patents.555,142 and. 602,943) in a. strong base, such: as. sodium or. potassium hydroxide, with:ahalo-carboxylioacid of the proper carboncontent. An alpha-halo-aliphaticcarbox-ylic. acid. is: preferred since itis, more readily obtained. The, product of the reactionis a 3,5- diiodo-4-pyridone-N-carboxylic:.acid,. theacid being. substituted. at. the position originally occupied byt thehalogen atom.
The: following 1 examples will. further. illustrate my invention and demonstrate;thegenerality of the reactions involved, without, however, limiting the scope of the invention thereto.
EXAMPLE 1 Alpha-n-butyl-3,5-diiodo-4-z1yridone-N-acetic acid 3,5-diiodo-4-pyridone (35.5 g.) is added to a solution of 4 g. of sodium hydroxide in 100 cc. of water and heated to give a turbid solution at 90-95 C. A solution of 19.5 g. of alpha-bromocaproic acid in 150 cc. of water containing 6 g. of sodium hydroxide is then added over a period of five minutes. Heating with stirring is continued for one and one-quarter hours longer, after which the mixture is cooled and carbon dioxide passed in until the solution is acid to phenylphthalein and all of the unreacted 3,5-diiodo-4- pyridone has been precipitated. The solid, about 20 g., is filtered, and the filtrate is cooled in ice and acidified with hydrochloric acid. A gum precipitates which is filtered and dissolved in alco- 1101. The alcohol solution is decolorized with activated charcoal, filtered, and diluted with an equal volume of water. Upon cooling and standing, the product crystallizes and is filtered, dissolved in ether, dried over anhydrous sodium sulfate, and again decolorized. After removal of the ether, the product is crystallized from dilute alcohol, filtered and dried; yield about 1'7 g., M. P. 205-207 C., of alpha-n-butyl-3,5-diiodo-4-pyridone-N-acetic acid.
EXAMPLE 2 Alpha-n-amyl-3,5-diiodo-4-pyridone-N-acetic acid 3,5-diiodo-4-pyridone (35 g.) and 23 g. of 2- bromoheptanoic acid are caused to react in the same manner as the components in Example 1. The final product, alpha-n-amyl-3,5-diiodo-4- pyridone-N-acetic acid, crystallizes from 50% alcohol and has the M. P. ZOO-203 C.
EXAMPLE 3 Alpha-n-hexyl-3,5-diiodo-4pyridoneN-acetic acid 3,5-diiodo-4-pyridone (109 g.) is dissolved in a solution of 14 g. of sodium hydroxide at 90 C. 2-bromooctanoic acid ('70 g, B. P. 97-110 C.) in alkaline solution is added with Stirring in three portions over a period of one and one-half hours as follows:
(1) Thirty grams of acid and 6.2 g. of sodium hydroxide in 100 cc. of water.
(2) Same as (1).
(3) Ten grams of acid and g. of sodium hydroxide in 50 cc. of water.
Heating is continued for two and one-half hours longer, 300 cc. of water added, and carbon dioxide is passed into the mixture until it is acid to phenolphthalein. The precipitated, unreacted 3,5-diiodo-4-pyridone (about 70 g.) is filtered and washed with water, and the filtrate is acidified with hydrochloric acid, producing a brown oily solid. The product is filtered, dissolved in alcohol, and decolorized by bubbling sulfur di Two more recrystallizations, each with a repeti-'- tion of the decolorizing procedure gives about 55 g. of alpha-n-hexyl-3,5-diiodo-e-pyridone-N- acetic'acid, M. P. 191-194" C.
4 EXAMPLE 4 Alpha-isoamyZ-3,5-diiodo-4-pyridone-N-acetic acid 3,5-diiodo-4-pyridone g.) and 50 g. of 2- bromo-5-methylhexanoic acid are caused to react in the same manner as the components in Example 3. About 57 g. of alpha-isoamyl-3,5- diiodo-4-pyridone-N-acetic acid is obtained having the M. P. 198.5-200.5 C.
EXAMPLE 5 EXAMPLE 6 Alpha-n-octyZ-3,5-diiodo-4-py'rid0ne-N-acetic acid 3,5-diiodo-4-pyridone (35 g.) and 25.1 g. of 2- bromodecanoic acid are caused to react in the same manner as the components in Example 1. The product, alpha-n-octyl-3,5-diiodo-4-pyridone-N-acetic acid, crystallizes from dilute alco- 1101 and has the M. P. 124.5-126.5 C.
EXAMPLE '7 Alpha-Jsobatyl-3,5-diiodo-4-pyridone-N-acetic acid 3,5-diiodo-4-pyridone (95 g.) and 46.6 g. of alpha-bromoisocaproic acid are caused to react in the same manner as the components in Example 3. Repeated recrystallization of the product from dilute alcohol gives about 36 g. of alphaisobutyl-3,5-diiodol-pyridone-N-acetic acid, M. P. -186 C.
In order to obtain water soluble radiopaque media, the acids prepared in the above examples, and others within the scope of the invention, can be dissolved in an aqueous solution of an equivalent amount of a suitable inorganic or organic base. Suitable bases are those which are innocuous and otherwise therapeutically acceptable to the organism; for example, sodium hydroxide, diethylamine and diethanolamine.
I claim:
1. A compound of the formula i l-000E where Y is an alkylene radical containing from 5 to 9 carbon atoms, and salts thereof.
2. A compound of the formula 0 II I' I1 N where R is an alkyl group containing from 4 to 8 carbon atoms, and salts thereof.
5 3. Alpha isobutyl 3,5 diiodo 4 pyridone- N-acetic acid having the formula i e OHs-GHCHr-CH-COOH and salts thereof.
4. Alpha isoamyl 3,5 diioclo 4 pyridone- N-acetic acid having the formula onaonornonl-oruo OOH and salts thereof.
5. Alpha-amyl-3,5-diiodo-4-pyridone-N-acetic acid having the formula I CHaCHaCHiCH:CHa-CHG O OH and salts thereof.
6. The process of preparing compounds of the formula where Y is an alkylene radical containing from 5 to 9 carbon atoms, which comprises reacting an alkali metal salt of 3,5-diiodo-4-pyridone with an alkali metal salt of a halo-carboxylic acid of the formula X--YCOOI-I where X is halogen, and recovering the resulting 3,5-diiodo-4-pyridone-N-carboxyllc acid.
'1. The process of preparing compounds of the formula I CHzCHaGHrOHr-OHC O OH and. salts thereof.
9. Alpha n hexyl 3,5 diiodo 4 pyrldone- N-acetic acid having the formula N OHJCHQCHQOHSOHQCHiHCOOH and salts thereof.
SYDNEY ARCHER.
REFERENCES CITED The following references are of record in the file of this patent:
UNITED STATES PATENTS Name Date Reitmann et a1. Dec. 22, 1936 Number
Claims (2)
1. A COMPOUND OF THE FORMULA
6. THE PROCESS OF PREPARING COMPOUNDS OF THE FORMULA
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US777864A US2505634A (en) | 1947-10-03 | 1947-10-03 | 4-pyridone-nu-carboxylic acids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US777864A US2505634A (en) | 1947-10-03 | 1947-10-03 | 4-pyridone-nu-carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2505634A true US2505634A (en) | 1950-04-25 |
Family
ID=25111543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US777864A Expired - Lifetime US2505634A (en) | 1947-10-03 | 1947-10-03 | 4-pyridone-nu-carboxylic acids |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2505634A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1028997B (en) * | 1952-07-31 | 1958-04-30 | Bayer Ag | Process for the preparation of halogenated pyridone derivatives of aliphatic carboxylic acids |
| US2995561A (en) * | 1959-01-09 | 1961-08-08 | Cilag Chemie | Certain nu-(3, 5-diiodo-4-pyridonealkanoyl)-aminoalkanoic acids |
| US3021260A (en) * | 1957-09-11 | 1962-02-13 | Bayer Ag | Mono-glycol esters of 3, 5-di-iodo-4-pyridone-nu-acetic acid X-ray contrast agentsin bronchography |
| US3235461A (en) * | 1966-02-15 | Esters of j,s-diiodo-x-pyridone-n- acetic acid | ||
| US3252985A (en) * | 1963-10-17 | 1966-05-24 | Cilag Chemie | Amides and their use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2064944A (en) * | 1930-12-20 | 1936-12-22 | Winthrop Chem Co Inc | Pyridine derivatives and process of making them |
-
1947
- 1947-10-03 US US777864A patent/US2505634A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2064944A (en) * | 1930-12-20 | 1936-12-22 | Winthrop Chem Co Inc | Pyridine derivatives and process of making them |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235461A (en) * | 1966-02-15 | Esters of j,s-diiodo-x-pyridone-n- acetic acid | ||
| DE1028997B (en) * | 1952-07-31 | 1958-04-30 | Bayer Ag | Process for the preparation of halogenated pyridone derivatives of aliphatic carboxylic acids |
| US3021260A (en) * | 1957-09-11 | 1962-02-13 | Bayer Ag | Mono-glycol esters of 3, 5-di-iodo-4-pyridone-nu-acetic acid X-ray contrast agentsin bronchography |
| US2995561A (en) * | 1959-01-09 | 1961-08-08 | Cilag Chemie | Certain nu-(3, 5-diiodo-4-pyridonealkanoyl)-aminoalkanoic acids |
| US3252985A (en) * | 1963-10-17 | 1966-05-24 | Cilag Chemie | Amides and their use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3957853A (en) | Metformine salt of acetylsalicylic acid | |
| PL96082B1 (en) | METHOD FOR THE PRODUCTION OF NEW BIS- / BIHYDROXYPROPYLAMIDES / 5-HYDROXYPROPIONYLAMINO-2,4,6-TRIODO-ISOPHTAL | |
| JPS60231648A (en) | Manufacture of diaryl compound | |
| JPS5668674A (en) | 5-fluorouracil derivative | |
| IE62460B1 (en) | New dicarboxylic acid-bis-(3,5-dicarbamoyl-2,4,6-triiodoanilides), process for their production as well as x-ray contrast media containing them | |
| WO1996019487A1 (en) | Organobismuth derivatives and process for producing the same | |
| US2505634A (en) | 4-pyridone-nu-carboxylic acids | |
| US3723446A (en) | {60 halopenoxy-isobutyroyl-{62 -nicotinoyl-glycols and processes therefor | |
| US3825591A (en) | Orally applicable contrast agents for cholecystography | |
| JPH09507210A (en) | Novel X-ray contrast agent, composition and method | |
| US2185220A (en) | Medicinal agent | |
| US2608507A (en) | Dialkyl sulfamyl benzoic acids | |
| DE69102069T2 (en) | 5-AMINOSALICYLIC ACID DERIVATIVES FOR THE TREATMENT OF CHRONICALLY INFLAMMABLE BELLY DISEASES. | |
| US2813118A (en) | X-ray contrast compounds | |
| US2724721A (en) | Mercaptals of halogenated salicyaldehydes | |
| US4001231A (en) | Process for making a methenamine salt of an optically active acid | |
| US3047466A (en) | X-ray contrast agent | |
| US3819821A (en) | X-ray opacifiers | |
| JPH07502031A (en) | 5,5'-/(1,3-propanediyl)bis/imino(2-oxo2,1-ethanediyl)acetylimino/bis(2,4,6-triiodo-1,3-benzenedicarboxyamide), and contrast agents containing these | |
| US3666800A (en) | Substituted triiodoisophthalamic acids | |
| US3553259A (en) | Contrast media for cholecystography | |
| US3359278A (en) | Nu-substituted-2, 4, 6-triiodoanilic acids and salts thereof | |
| US2790748A (en) | Contrast agent | |
| DE2038836A1 (en) | drug | |
| US3553260A (en) | Radiopaque derivatives of alpha-phenoxy-phenylacetic acid |